<The> sustained virologic response and adverse effects of peg interferon alfa and ribavirin in the treatment of patients with chronic hepatitis c: a study from Iran

Simin, Shoaei; Shahnaz, Sali; Azadeh, Lali; Mehdi, Karamipour; Javad, Minooeefar

sustained virologic response and adverse effects of peg interferon alfa and ribavirin in the treatment of patients with chronic hepatitis c: a study from Iran

Simin, Shoaei; Shahnaz, Sali; Azadeh, Lali; Mehdi, Karamipour; Javad, Minooeefar.

Novelty in Biomedicine. 2017; 5 (4): 172-176

em Inglês | IMEMR | ID: emr-189668

ABSTRACT

ABSTRACT

Background:

Hepatitis C infection is a worldwide problem. In Iran, hepatitis C virus [HCV] infection prevalence is about 1-2%. A combination therapy of pegylated interferon alfa-2a and ribavirin [PEG-IFNalpha/RBV] is a standard treatment, but our aim was to determine the efficacy and safety of dual PEG-IFNalpha/RBV therapy in treating patients infected with HCV in Iranian context

Assuntos

Humanos; Masculino; Feminino; Adulto; Interferon-alfa/efeitos adversos; Ribavirina/efeitos adversos; Quimioterapia Combinada; Fatores de Risco; Estudos Transversais; Estudos Prospectivos

Buscar no Google

Imprimir

XML

Índice: IMEMR (Mediterrâneo Oriental) Assunto principal: Ribavirina / Estudos Transversais / Estudos Prospectivos / Fatores de Risco / Interferon-alfa / Quimioterapia Combinada Tipo de estudo: Estudo de prevalência Limite: Adulto / Feminino / Humanos / Masculino Idioma: Inglês Revista: Novelty Biomed. Ano de publicação: 2017

Similares

MEDLINE

LILACS

LIS

Buscar no Google

Imprimir

XML